Information de reference pour ce titreAccession Number: | 01714644-201810000-00017.
|
Author: | Dougherty, Darin D. MD 1,2,3,4; Brennan, Brian P. MD; MMSc 2,4,5; Stewart, S. Evelyn MD 6; Wilhelm, Sabine PhD 3,4; Widge, Alik S. MD; PhD 1,4,7; Rauch, Scott L. MD 2,4
|
Institution: | (1)Division of Neurotherapeutics, Massachusetts General Hospital, Boston (2)Obsessive-Compulsive Disorder Institute, McLean Hospital, Belmont, Massachusetts (3)Obsessive-Compulsive and Related Disorders Program, Massachusetts General Hospital, Boston (4)Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (5)Biological Psychiatry Laboratory, McLean Hospital, Belmont, Massachusetts (6)BC Mental Health & Addictions Research Institute, University of British Columbia, Vancouver, British Columbia, Canada (7)Picower Institute for Learning and Memory, Massachusetts Institute for Technology, Cambridge Corresponding Author: Darin D. Dougherty, MD, Department of Psychiatry, Massachusetts General Hospital, 149 Thirteenth St, Office 2612, Charlestown, MA 02129 ( [email protected]).
|
Title: | |
Source: | JAMA Psychiatry. 75(10):1081-1087, October 2018.
|
Abstract: | Importance: Obsessive-compulsive disorder (OCD) is a common and often debilitating psychiatric illness. Recent advances in the understanding of the neuroscience of OCD have provided valuable insights that have begun to transform the way we think about the management of this disorder. This educational review provides an integrated neuroscience perspective on formulation and treatment planning for patients with OCD. The article is organized around key neuroscience themes most relevant for OCD.
Observations: An integrated neuroscience formulation of OCD is predicated on a fundamental understanding of phenomenology and symptom dimensions, fear conditioning and extinction, neurochemistry, genetics and animal models, as well as neurocircuitry and neurotherapeutics. Symptom dimensions provide a means to better understand the phenotypic heterogeneity within OCD with an eye toward more personalized treatments. The concept of abnormal fear extinction is central to OCD and to the underlying therapeutic mechanism of exposure and response prevention. A framework for understanding the neurochemistry of OCD focuses on both traditional monoaminergic systems and more recent evidence of glutamatergic and [gamma]-aminobutyric acid-ergic dysfunction. Obsessive-compulsive disorder is highly heritable, and future work is needed to understand the contribution of genes to underlying pathophysiology. A circuit dysregulation framework focuses on cortico-striato-thalamo-cortical circuit dysfunction and the development of neurotherapeutic approaches targeting this circuit. The impact of these concepts on how we think about OCD diagnosis and treatment is discussed. Suggestions for future investigations that have the potential to further enhance the clinical management of OCD are presented.
Conclusions and Relevance: These key neuroscience themes collectively inform formulation and treatment planning for patients with OCD. The ultimate goal is to increase crosstalk between clinicians and researchers in an effort to facilitate translation of advances in neuroscience research to improved care for patients with OCD.
Copyright 2018 by the American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. American Medical Association, 515 N. State St, Chicago, IL 60610.
|
References: | 1. Stone MH. Introduction: The history of obsessive-compulsive disorder from the early period to the turn of the twentieth century. In: Stein DJ, Stone MH, eds. Essential Papers on Obsessive-Compulsive Disorder. New York: New York University Press; 1997:19-33.
2. Brennan BP, Jacoby RJ, Widge AS. A case of severe intractable contamination-based obsessive-compulsive disorder [published online August 15, 2018]. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2018.0927
3. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder: I: a controlled clinical trial. Arch Gen Psychiatry. 1980;37(11):1281-1285. doi:10.1001/archpsyc.1980.01780240079009
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
5. Stein DJ, Fineberg NA, Bienvenu OJ, et al. Should OCD be classified as an anxiety disorder in DSM-V? Depress Anxiety. 2010;27(6):495-506. doi:10.1002/da.20699
6. Phillips KA, Stein DJ, Rauch SL, et al. Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V? Depress Anxiety. 2010;27(6):528-555. doi:10.1002/da.20705
7. Milad MR, Furtak SC, Greenberg JL, et al. Deficits in conditioned fear extinction in obsessive-compulsive disorder and neurobiological changes in the fear circuit. JAMA Psychiatry. 2013;70(6):608-618. doi:10.1001/jamapsychiatry.2013.914
8. Steketee G, Frost RO, Cohen I. Beliefs in obsessive-compulsive disorder. J Anxiety Disord. 1998;12(6):525-537. doi:10.1016/S0887-6185(98)00030-9
9. Moritz S, Von Muhlenen A, Randjbar S, Fricke S, Jelinek L. Evidence for an attentional bias for washing- and checking-relevant stimuli in obsessive-compulsive disorder. J Int Neuropsychol Soc. 2009;15(3):365-371. doi:10.1017/S1355617709090511
10. Boelen PA, Carleton RN. Intolerance of uncertainty, hypochondriacal concerns, obsessive-compulsive symptoms, and worry. J Nerv Ment Dis. 2012;200(3):208-213. doi:10.1097/NMD.0b013e318247cb17
11. Riesel A, Weinberg A, Endrass T, Kathmann N, Hajcak G. Punishment has a lasting impact on error-related brain activity. Psychophysiology. 2012;49(2):239-247. doi:10.1111/j.1469-8986.2011.01298.x
12. Voon V, Derbyshire K, Ruck C, et al. Disorders of compulsivity: a common bias towards learning habits. Mol Psychiatry. 2015;20(3):345-352. doi:10.1038/mp.2014.44
13. Shin NY, Lee TY, Kim E, Kwon JS. Cognitive functioning in obsessive-compulsive disorder: a meta-analysis. Psychol Med. 2014;44(6):1121-1130. doi:10.1017/S0033291713001803
14. Chamberlain SR, Blackwell AD, Fineberg NA, Robbins TW, Sahakian BJ. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev. 2005;29(3):399-419. doi:10.1016/j.neubiorev.2004.11.006
15. Apergis-Schoute AM, Gillan CM, Fineberg NA, Fernandez-Egea E, Sahakian BJ, Robbins TW. Neural basis of impaired safety signaling in obsessive compulsive disorder. Proc Natl Acad Sci U S A. 2017;114(12):3216-3221. doi:10.1073/pnas.1609194114
16. Brennan BP, Rauch SL. Functional neuroimaging studies in obsessive-compulsive disorder: overview and synthesis. In: Pittenger C, ed. Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment. New York, NY: Oxford University Press; 2017:213-231.
17. Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012;16(1):43-51. doi:10.1016/j.tics.2011.11.003
18. Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004;24(8):1011-1030. doi:10.1016/j.cpr.2004.08.004
19. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am. 2014;37(3):375-391. doi:10.1016/j.psc.2014.05.006
20. Graat I, Figee M, Denys D. Neurotransmitter dysfunction in OCD. In: Pittenger C, ed. Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment. New York, NY: Oxford University Press; 2017:271-288.
21. Jenike MA. Clinical practice: obsessive-compulsive disorder. N Engl J Med. 2004;350(3):259-265. doi:10.1056/NEJMcp031002
22. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622-632. doi:10.1038/sj.mp.4001823
23. Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2013;16(3):557-574. doi:10.1017/S1461145712000740
24. Moore GJ, MacMaster FP, Stewart C, Rosenberg DR. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1998;37(6):663-667. doi:10.1097/00004583-199806000-00017
25. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry. 2000;39(9):1096-1103. doi:10.1097/00004583-200009000-00008
26. Brennan BP, Rauch SL, Jensen JE, Pope HG Jr. A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder. Biol Psychiatry. 2013;73(1):24-31. doi:10.1016/j.biopsych.2012.06.023
27. Marinova Z, Chuang DM, Fineberg N. Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder. Curr Neuropharmacol. 2017;15(7):977-995. doi:10.2174/1570159X15666170320104237
28. Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475-2483. doi:10.1038/npp.2013.150
29. Bloch MH, Wasylink S, Landeros-Weisenberger A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012;72(11):964-970. doi:10.1016/j.biopsych.2012.05.028
30. Richter MA, de Jesus DR, Hoppenbrouwers S, et al. Evidence for cortical inhibitory and excitatory dysfunction in obsessive compulsive disorder. Neuropsychopharmacology. 2012;37(5):1144-1151. doi:10.1038/npp.2011.300
31. Simpson HB, Shungu DC, Bender J Jr, et al. Investigation of cortical glutamate-glutamine and [gamma]-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy. Neuropsychopharmacology. 2012;37(12):2684-2692. doi:10.1038/npp.2012.132
32. Zhang Z, Fan Q, Bai Y, Wang Z, Zhang H, Xiao Z. Brain gamma-aminobutyric acid (GABA) concentration of the prefrontal lobe in unmedicated patients with obsessive-compulsive disorder: a research of magnetic resonance spectroscopy. Shanghai Arch Psychiatry. 2016;28(5):263-270.
33. Rodriguez CI, Kegeles LS, Levinson A, et al. In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: proof of concept. Psychiatry Res. 2015;233(2):141-147. doi:10.1016/j.pscychresns.2015.06.001
34. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153(4):466-476. doi:10.1176/ajp.153.4.466
35. Monckton JE, McCormick DA. Neuromodulatory role of serotonin in the ferret thalamus. J Neurophysiol. 2002;87(4):2124-2136. doi:10.1152/jn.00650.2001
36. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev. 1995;20(1):91-127. doi:10.1016/0165-0173(94)00007-C
37. Nestadt G, Samuels J, Riddle M, et al. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57(4):358-363. doi:10.1001/archpsyc.57.4.358
38. van Grootheest DS, Cath DC, Beekman AT, Boomsma DI. Twin studies on obsessive-compulsive disorder: a review. Twin Res Hum Genet. 2005;8(5):450-458. doi:10.1375/twin.8.5.450
39. Bandelow B, Baldwin D, Abelli M, et al. Biological markers for anxiety disorders, OCD and PTSD: a consensus statement, part I: neuroimaging and genetics. World J Biol Psychiatry. 2016;17(5):321-365. doi:10.1080/15622975.2016.1181783
40. Stewart SE, Mayerfeld C, Arnold PD, et al. Meta-analysis of association between obsessive-compulsive disorder and the 3' region of neuronal glutamate transporter gene SLC1A1. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(4):367-379. doi:10.1002/ajmg.b.32137
41. Stewart SE, Yu D, Scharf JM, et alNorth American Brain Expression ConsortiumUK Brain Expression Database. Genome-wide association study of obsessive-compulsive disorder [published correction appears in Mol Psychiatry. 2013;18(7):843]. Mol Psychiatry. 2013;18(7):788-798. doi:10.1038/mp.2012.85
42. Mattheisen M, Samuels JF, Wang Y, et al. Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS. Mol Psychiatry. 2015;20(3):337-344. doi:10.1038/mp.2014.43
43. International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC)OCD Collaborative Genetics Association Studies (OCGAS). Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. Mol Psychiatry. 2018;23(5):1181-1188. doi:10.1038/mp.2017.154
44. Ahmari SE, Dougherty DD. Dissecting OCD circuits: from animal models to targeted treatments. Depress Anxiety. 2015;32(8):550-562. doi:10.1002/da.22367
45. Pauls DL, Abramovitch A, Rauch SL, Geller DA. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev Neurosci. 2014;15(6):410-424. doi:10.1038/nrn3746
46. Welch JM, Lu J, Rodriguiz RM, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature. 2007;448(7156):894-900. doi:10.1038/nature06104
47. Guo W, Samuels JF, Wang Y, et al. Polygenic risk score and heritability estimates reveals a genetic relationship between ASD and OCD. Eur Neuropsychopharmacol. 2017;27(7):657-666. doi:10.1016/j.euroneuro.2017.03.011
48. McGrath LM, Yu D, Marshall C, et al. Copy number variation in obsessive-compulsive disorder and Tourette syndrome: a cross-disorder study. J Am Acad Child Adolesc Psychiatry. 2014;53(8):910-919. doi:10.1016/j.jaac.2014.04.022
49. Yu D, Mathews CA, Scharf JM, et al. Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry. 2015;172(1):82-93. doi:10.1176/appi.ajp.2014.13101306
50. Qin H, Samuels JF, Wang Y, et al. Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Mol Psychiatry. 2016;21(2):270-276. doi:10.1038/mp.2015.32
51. Nagarajan N, Jones BW, West PJ, Marc RE, Capecchi MR. Corticostriatal circuit defects in Hoxb8 mutant mice [published online November 28, 2017]. Mol Psychiatry. doi:10.1038/mp.2017.251
52. Song M, Mathews CA, Stewart SE, et al. Rare synaptogenesis-impairing mutations in SLITRK5 are associated with obsessive compulsive disorder. PLoS One. 2017;12(1):e0169994. doi:10.1371/journal.pone.0169994
53. Noh HJ, Tang R, Flannick J, et al. Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder. Nat Commun. 2017;8(1):774. doi:10.1038/s41467-017-00831-x
54. Mataix-Cols D, Frans E, Perez-Vigil A, et al. A total-population multigenerational family clustering study of autoimmune diseases in obsessive-compulsive disorder and Tourette's/chronic tic disorders [published online November 14, 2017]. Mol Psychiatry. doi:10.1038/mp.2017.215
55. Graybiel AM, Rauch SL. Toward a neurobiology of obsessive-compulsive disorder. Neuron. 2000;28(2):343-347. doi:10.1016/S0896-6273(00)00113-6
56. Robbins TW, Gillan CM, Smith DG, de Wit S, Ersche KD. Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. Trends Cogn Sci. 2012;16(1):81-91. doi:10.1016/j.tics.2011.11.009
57. Haber SN. Corticostriatal circuitry. Dialogues Clin Neurosci. 2016;18(1):7-21.
58. Anticevic A, Hu S, Zhang S, et al. Global resting-state functional magnetic resonance imaging analysis identifies frontal cortex, striatal, and cerebellar dysconnectivity in obsessive-compulsive disorder. Biol Psychiatry. 2014;75(8):595-605. doi:10.1016/j.biopsych.2013.10.021
59. Vaghi MM, Hampshire A, Fineberg NA, et al. Hypoactivation and dysconnectivity of a frontostriatal circuit during goal-directed planning as an endophenotype for obsessive-compulsive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017;2(8):655-663. doi:10.1016/j.bpsc.2017.05.005
60. Vaghi MM, Vertes PE, Kitzbichler MG, et al. Specific frontostriatal circuits for impaired cognitive flexibility and goal-directed planning in obsessive-compulsive disorder: evidence from resting-state functional connectivity. Biol Psychiatry. 2017;81(8):708-717. doi:10.1016/j.biopsych.2016.08.009
61. Abramovitch A, Abramowitz JS, Mittelman A. The neuropsychology of adult obsessive-compulsive disorder: a meta-analysis. Clin Psychol Rev. 2013;33(8):1163-1171. doi:10.1016/j.cpr.2013.09.004
62. Gillan CM, Morein-Zamir S, Urcelay GP, et al. Enhanced avoidance habits in obsessive-compulsive disorder. Biol Psychiatry. 2014;75(8):631-638. doi:10.1016/j.biopsych.2013.02.002
63. Burguiere E, Monteiro P, Feng G, Graybiel AM. Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors. Science. 2013;340(6137):1243-1246. doi:10.1126/science.1232380
64. Ahmari SE, Spellman T, Douglass NL, et al. Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science. 2013;340(6137):1234-1239. doi:10.1126/science.1234733
65. Keen EC, Widge AS, Dougherty DD. Functional neurosurgery in severe and treatment-refractory OCD. In: Pittenger C, ed. Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment. New York, NY: Oxford University Press; 2017.
66. Lopes AC, Greenberg BD, Canteras MM, et al. Gamma ventral capsulotomy for obsessive-compulsive disorder: a randomized clinical trial [retracted in: JAMA Psychiatry. 2015;71(12):1258]. JAMA Psychiatry. 2014;71(9):1066-1076. doi:10.1001/jamapsychiatry.2014.1193
67. Lapidus KA, Stern ER, Berlin HA, Goodman WK. Neuromodulation for obsessive-compulsive disorder. Neurotherapeutics. 2014;11(3):485-495. doi:10.1007/s13311-014-0287-9
68. Trevizol AP, Shiozawa P, Cook IA, et al. Transcranial magnetic stimulation for obsessive-compulsive disorder: an updated systematic review and meta-analysis. J ECT. 2016;32(4):262-266. doi:10.1097/YCT.0000000000000335
69. Mallet L, Polosan M, Jaafari N, et alSTOC Study Group. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008;359(20):2121-2134. doi:10.1056/NEJMoa0708514
70. Luyten L, Hendrickx S, Raymaekers S, Gabriels L, Nuttin B. Electrical stimulation in the bed nucleus of the stria terminalis alleviates severe obsessive-compulsive disorder. Mol Psychiatry. 2016;21(9):1272-1280. doi:10.1038/mp.2015.124
71. Widge AS, Dougherty DD. Deep brain stimulation for treatment-refractory mood and obsessive-compulsive disorders. Curr Behav Neurosci Rep. 2015;2(4):187-197. doi:10.1007/s40473-015-0049-y
72. Dougherty DD, Chou T, Corse AK, et al. Acute deep brain stimulation changes in regional cerebral blood flow in obsessive-compulsive disorder. J Neurosurg. 2016;125(5):1087-1093. doi:10.3171/2015.9.JNS151387
73. Lo MC, Widge AS. Closed-loop neuromodulation systems: next-generation treatments for psychiatric illness. Int Rev Psychiatry. 2017;29(2):191-204. doi:10.1080/09540261.2017.1282438
74. Widge AS, Licon E, Zorowitz S, et al. Predictors of hypomania during ventral capsule/ventral striatum deep brain stimulation. J Neuropsychiatry Clin Neurosci. 2016;28(1):38-44. doi:10.1176/appi.neuropsych.15040089
75. Widge AS, Ellard KK, Paulk AC, et al. Treating refractory mental illness with closed-loop brain stimulation: progress towards a patient-specific transdiagnostic approach. Exp Neurol. 2017;287(Pt 4):461-472. doi:10.1016/j.expneurol.2016.07.021
|
Language: | English.
|
Document Type: | Review: Review.
|
ISSN: | 2168-622X
|
DOI Number: | https://dx.doi.org/10.1001/jamap...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|